Literature DB >> 22496590

Loss of XLαs (extra-large αs) imprinting results in early postnatal hypoglycemia and lethality in a mouse model of pseudohypoparathyroidism Ib.

Eduardo Fernández-Rebollo1, Akira Maeda, Monica Reyes, Serap Turan, Leopold F Fröhlich, Antonius Plagge, Gavin Kelsey, Harald Jüppner, Murat Bastepe.   

Abstract

Maternal deletion of the NESP55 differentially methylated region (DMR) (delNESP55/ASdel3-4(m), delNAS(m)) from the GNAS locus in humans causes autosomal dominant pseudohypoparathyroidism type Ib (AD-PHP-Ib(delNASm)), a disorder of proximal tubular parathyroid hormone (PTH) resistance associated with loss of maternal GNAS methylation imprints. Mice carrying a similar, maternally inherited deletion of the Nesp55 DMR (ΔNesp55(m)) replicate these Gnas epigenetic abnormalities and show evidence for PTH resistance, yet these mice demonstrate 100% mortality during the early postnatal period. We investigated whether the loss of extralarge αs (XLαs) imprinting and the resultant biallelic expression of XLαs are responsible for the early postnatal lethality in ΔNesp55(m) mice. First, we found that ΔNesp55(m) mice are hypoglycemic and have reduced stomach-to-body weight ratio. We then generated mice having the same epigenetic abnormalities as the ΔNesp55(m) mice but with normalized XLαs expression due to the paternal disruption of the exon giving rise to this Gnas product. These mice (ΔNesp55(m)/Gnasxl(m+/p-)) showed nearly 100% survival up to postnatal day 10, and a substantial number of them lived to adulthood. The hypoglycemia and reduced stomach-to-body weight ratio observed in 2-d-old ΔNesp55(m) mice were rescued in the ΔNesp55(m)/Gnasxl(m+/p-) mice. Surviving double-mutant animals had significantly reduced Gαs mRNA levels and showed hypocalcemia, hyperphosphatemia, and elevated PTH levels, thus providing a viable model of human AD-PHP-Ib. Our findings show that the hypoglycemia and early postnatal lethality caused by the maternal deletion of the Nesp55 DMR result from biallelic XLαs expression. The double-mutant mice will help elucidate the pathophysiological mechanisms underlying AD-PHP-Ib.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496590      PMCID: PMC3340037          DOI: 10.1073/pnas.1117608109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Alternative promoter and 5' exon generate a novel Gs alpha mRNA.

Authors:  Y Ishikawa; C Bianchi; B Nadal-Ginard; C J Homcy
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

Review 2.  Control of imprinting at the Gnas cluster.

Authors:  Jo Peters; Christine M Williamson
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  XL alpha s is a new type of G protein.

Authors:  R H Kehlenbach; J Matthey; W B Huttner
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

4.  Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.

Authors:  B E Hayward; A Barlier; M Korbonits; A B Grossman; P Jacquet; A Enjalbert; D T Bonthron
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 5.  Imprinting on chromosome 20: tissue-specific imprinting and imprinting mutations in the GNAS locus.

Authors:  Gavin Kelsey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2010-08-15       Impact factor: 3.908

6.  Receptor-mediated adenylyl cyclase activation through XLalpha(s), the extra-large variant of the stimulatory G protein alpha-subunit.

Authors:  Murat Bastepe; Yasemin Gunes; Beatriz Perez-Villamil; Joy Hunzelman; Lee S Weinstein; Harald Jüppner
Journal:  Mol Endocrinol       Date:  2002-08

7.  XLalphas, the extra-long form of the alpha-subunit of the Gs G protein, is significantly longer than suspected, and so is its companion Alex.

Authors:  Joel Abramowitz; Dagoberto Grenet; Mariel Birnbaumer; Hector N Torres; Lutz Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

8.  Transcription is required for establishment of germline methylation marks at imprinted genes.

Authors:  Mita Chotalia; Sebastien A Smallwood; Nico Ruf; Claire Dawson; Diana Lucifero; Marga Frontera; Katherine James; Wendy Dean; Gavin Kelsey
Journal:  Genes Dev       Date:  2009-01-01       Impact factor: 11.361

Review 9.  The GNAS locus and pseudohypoparathyroidism.

Authors:  Murat Bastepe
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

10.  Control of bone mass and remodeling by PTH receptor signaling in osteocytes.

Authors:  Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  14 in total

1.  Analysis of Multiple Families With Single Individuals Affected by Pseudohypoparathyroidism Type Ib (PHP1B) Reveals Only One Novel Maternally Inherited GNAS Deletion.

Authors:  Rieko Takatani; Angelo Molinaro; Giedre Grigelioniene; Olta Tafaj; Tomoyuki Watanabe; Monica Reyes; Amita Sharma; Vibha Singhal; F Lucy Raymond; Agnès Linglart; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2015-11-14       Impact factor: 6.741

2.  Postnatal establishment of allelic Gαs silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous Gαs disruption.

Authors:  Serap Turan; Eduardo Fernandez-Rebollo; Cumhur Aydin; Teuta Zoto; Monica Reyes; George Bounoutas; Min Chen; Lee S Weinstein; Reinhold G Erben; Vladimir Marshansky; Murat Bastepe
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

3.  A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23.

Authors:  Qing He; Lauren T Shumate; Julia Matthias; Cumhur Aydin; Marc N Wein; Jordan M Spatz; Regina Goetz; Moosa Mohammadi; Antonius Plagge; Paola Divieti Pajevic; Murat Bastepe
Journal:  JCI Insight       Date:  2019-09-05

Review 4.  GNAS Spectrum of Disorders.

Authors:  Serap Turan; Murat Bastepe
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

Review 5.  The GNAS complex locus and human diseases associated with loss-of-function mutations or epimutations within this imprinted gene.

Authors:  Serap Turan; Murat Bastepe
Journal:  Horm Res Paediatr       Date:  2013-10-03       Impact factor: 2.852

6.  Large G protein α-subunit XLαs limits clathrin-mediated endocytosis and regulates tissue iron levels in vivo.

Authors:  Qing He; Richard Bouley; Zun Liu; Marc N Wein; Yan Zhu; Jordan M Spatz; Chia-Yu Wang; Paola Divieti Pajevic; Antonius Plagge; Jodie L Babitt; Murat Bastepe
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-23       Impact factor: 11.205

7.  Ablation of the Stimulatory G Protein α-Subunit in Renal Proximal Tubules Leads to Parathyroid Hormone-Resistance With Increased Renal Cyp24a1 mRNA Abundance and Reduced Serum 1,25-Dihydroxyvitamin D.

Authors:  Yan Zhu; Qing He; Cumhur Aydin; Isabelle Rubera; Michel Tauc; Min Chen; Lee S Weinstein; Vladimir Marshansky; Harald Jüppner; Murat Bastepe
Journal:  Endocrinology       Date:  2015-12-15       Impact factor: 4.736

8.  Extra-Large Gα Protein (XLαs) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation.

Authors:  Julia Matthias; Qiuxia Cui; Lauren T Shumate; Antonius Plagge; Qing He; Murat Bastepe
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

Review 9.  The role of genomic imprinting in biology and disease: an expanding view.

Authors:  Jo Peters
Journal:  Nat Rev Genet       Date:  2014-06-24       Impact factor: 53.242

10.  The G protein α subunit variant XLαs promotes inositol 1,4,5-trisphosphate signaling and mediates the renal actions of parathyroid hormone in vivo.

Authors:  Qing He; Yan Zhu; Braden A Corbin; Antonius Plagge; Murat Bastepe
Journal:  Sci Signal       Date:  2015-08-25       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.